ArticleJournal of cosmetic dermatology2025
Phenol-Croton Oil Application in the Treatment of Xanthelasma Palpebrarum.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phenol-Croton Oil Application in the Treatment of Xanthelasma Palpebrarum.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundXanthelasma palpebrarum (XP) can cause significant cosmetic problems, and no standard treatment approach exists.
aimTo evaluate the outcomes of phenol-croton oil application in XP.
methodThe medical files and photographs of 10 patients treated with the topical application of 60% phenol and 1% croton oil solution (PCO) were retrospectively analyzed. Demographic and clinical features of the patients, XP severity, extent of XP lesions, and treatment outcomes were reviewed. The cosmetic outcomes were evaluated with the physician's and patient's visual analog scale (VAS) scores (from 1 to 6), and adverse effects and patient comments about the procedure were reviewed from the records.
resultsThe study included five males and five females with a range of 30-62 years of age. The XP severity score ranged between 5 and 10, and 60% of patients had severe disease. Nine patients (90%) benefited from the treatment; six (60%) were cured, and more than 60% improvement was observed in three patients after one to three sessions of PCO application. Postprocedural erythema occurred in three patients and faded in time. Postinflammatory hypopigmentation was observed in four patients and was hardly noticeable in follow-ups. Most patients expressed their impression of the cosmetic outcome as a VAS score of 5 or more. Except for one who was unhappy with the dyspigmentation, all patients stated that they would recommend the procedure to other patients with XP seeking treatment.
conclusionTopical PCO application on XP lesions is a safe, easily applicable, and cost-effective treatment option requiring few sessions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.